CV Sciences, Inc. Annual report [Section 13 and 15(d), not S-K Item 405]

Annual report [Section 13 and 15(d), not S-K Item 405]

Segment Data (Tables)

Segment Data (Tables)

12 Months Ended

Dec. 31, 2024

Schedule of Reportable Segment Product Sales, Net and Net income (Loss)

The Company's reportable segment product sales, net and net income (loss) for the years ended December 31, 2024 and 2023 consisted of the following (in thousands):


	For the Years Ended December 31,
	2024			2023
Product sales, net	$	15,705		$	16,004
Cost of goods sold		8,537			8,919
Gross profit		7,168			7,085

Operating expenses:
Research and development expense		118			151
Sales expense		3,166			3,065
Marketing expense		2,088			2,940
General and administrative expense		3,986			3,740
Benefit from reversal of accrued payroll taxes		—			(6,171	)
Total operating expenses		9,358			3,725

Operating income (loss)		(2,190	)		3,360
Other expense, net		212			264
Income (loss) before income taxes		(2,402	)		3,096
Income tax benefit		(8	)		(6	)
Net income (loss)	$	(2,394	)	$	3,102